Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 571 to 585 of 1112 results for criteria

  1. Radiofrequency ablation for colorectal liver metastases (IPG327)

    Evidence-based recommendations on radiofrequency ablation for the treatment of colorectal liver metastases. This involves using heat to destroy cancer cells in the liver.

    Interventional procedures guidance
    Published
    16 December 2009
    View recommendations

    Sections for IPG327

  2. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA161

  3. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.

    HealthTech guidance
    Last updated
    2 May 2024
    View recommendations

    Sections for HTG708

  4. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

    Technology appraisal guidance
    Published
    22 August 2018
    View recommendations

    Sections for TA538

  5. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

    Technology appraisal guidance
    Published
    5 February 2025
    View recommendations

    Sections for TA1036

  6. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2019
    View recommendations

    Sections for TA595

  7. Signs and symptoms that predict neutropenic sepsis in the community:- A prospective study should be carried out to determine which signs and symptoms experienced by patients in the community predict neutropenic sepsis and the outcomes of these episodes.

    invasive testing and increase resource use by the health service. Referral criteria that are too narrow will delay the emergency...

    Research recommendation
    Published
    9 June 2015

  8. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

    Technology appraisal guidance
    Published
    25 April 2012
    View recommendations

    Sections for TA254

  9. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA428

  10. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

    Technology appraisal guidance
    Published
    9 October 2019
    View recommendations

    Sections for TA605

  11. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  12. Imaging options in occult hip fracture: In people with a continuing suspicion of a hip fracture but whose radiographs are normal, what is the clinical and cost effectiveness of CT compared with MRI, in confirming or excluding the fracture?

    as the 'gold standard' for cases of uncertainty and to standardise the criteria, expertise and procedures for radiological assessment....

    Research recommendation
    Published
    3 February 2023

  13. The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care (MIB17)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care

    Medtech innovation briefing
    Published
    16 December 2014

  14. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

    Medtech innovation briefing
    Published
    22 May 2015

  15. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

    HealthTech guidance
    Published
    25 April 2018
    View recommendations

    Sections for HTG467